Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972407 · ClinicalTrials.gov registry record · Phase 2
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
A Phase 2 study, sponsored by Mayo Clinic.
- Not yet
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT06972407: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT06972407 is a Phase 2 study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06972407, a Phase 2 study, has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. Common genetic variation in the TCF7L2 locus (T-allele at rs7903146) arguably confers the greatest genetic risk of T2DM. It is associated with α- and β-cell dysfunction. TCF7L2 (the product of TCF7L2) was first described as the transcription factor necessary for proglucagon expression in intestinal L-cells (which secrete GLP-1). This led to speculation that TCF7L2 confers risk of diabetes via changes in circulating GLP-1. This has turned out to not be the case. This raises the possibility that these diabetogenic effects are mediated via an inability of islet GLP-1 to adapt to rising glycemia. Therefore, this experiment will determine the contribution of islet GLP-1 to the functional abnormalities of the islet associated with the TCF7L2 locus.
Interventions
- BIOLOGICAL Exendin 9-39
- OTHER Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06972407
The ClinicalTrials.gov registry entry for NCT06972407 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exendin 9-39 is the first listed.
NCT06972407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06972407 about?
NCT06972407 is a clinical study titled "The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans". The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of...
What is the current status of trial NCT06972407?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-10-01. Estimated completion is 2029-03-01.
What interventions are being tested in trial NCT06972407?
The interventions under investigation include: Exendin 9-39 (BIOLOGICAL), Saline (OTHER).
Who is sponsoring clinical trial NCT06972407?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.